This program will review the current data on the use of antiplatelet agents in the management of patients with Acute Coronary Syndromes (ACS), discuss the current guideline and emerging strategies for the use of adjunctive therapies in patients undergoing percutaneous coronary intervention (PCI), and apply strategies to improve outcomes and develop optimal discharge plans/protocols utilizing antiplatelet agents in patients with ACS.
This course is open to all healthcare providers and is targeted to primary care providers - Physicians, PAs, NPs, RNs, and Pharmacists.
After taking part in this educational activity, participants should be better able to:
- Review the current data on the use of antiplatelet agents in the management of patients with Acute Coronary Syndromes (ACS)
- Discuss the current guideline and emerging strategies for the use of adjunctive therapies in patients undergoing percutaneous coronary intervention (PCI)
- Apply strategies to improve outcomes and develop optimal discharge plans/protocols utilizing antiplatelet agents in patients with ACS
AMA PRA Category 1 Credit(s)TM
The Foundation for Care Management (FCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for Physicians.
FCM designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of the participation in the activity.
CE for Pharmacists
The Foundation for Care Management is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program #0347-0000-13-002-L01-P.
*This CE activity is knowledge-based (K). Objectives 1, 3, and 4 are appropriate for Pharmacists.
CE for Nurses
The Foundation for Care Management is an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Professor of Medicine, Harvard Medical School
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program,
Brigham and Women's Hospital and VA Boston Healthcare System
Senior Investigator, TIMI Study Group
It is the policy of Foundation for Care Management (FCM) to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may bementioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by FCM prior to accreditation of the activity. FCM planners and reviewers, outside of those listed, have no relevant financial relationships to disclose.
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Advisory Board: Medscape Cardiology
Board of Directors: Boston VA Research Institute, Society of Chest Pain Centers
Chair: American Heart Association Get With The Guidelines Science Subcommittee
Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME steering committees)
Other: Senior Associate Editor, Journal of Invasive Cardiology;
Research Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda.
FCM’s Planning Committee:
George Gey, MD, Allen Montgomery, RPh, Jeanette M. Dunn, EdD, RN, and Carole Mutzebaugh, EdD, NP, have no significant financial interest in any of the products or manufacturers mentioned.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint-sponsored by The Foundation for Care Management and CME-University.
This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.
Method of Participation:
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.
If you have any questions relating to the accreditation for this activity, please contact email@example.com.
If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.